FDA approves Jetrea for symptomatic vitreomacular adhesion in the eyes

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA approves Jetrea for symptomatic vitreomacular adhesion in the eyes

You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

FDA approves Jetrea for symptomatic vitreomacular adhesion in the eyes

10/18/2012 09:48 AM EDT

On Oct. 17, the U.S. Food and Drug Administration approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420